https://doi.org/10.55788/1a6fe7ba
Prospective, multicentre data on neurological manifestations of COVID-19 are still scarce. A prospective, observational study of hospitalised adults with laboratory-confirmed SARS-CoV-2 infection described the prevalence, associated risk factors, and outcomes of serious neurological manifestations, notably encephalopathy, stroke, seizure, and meningo-encephalitis. The database consisted of 16,225 hospitalised adults in 179 hospitals in 24 countries, enrolled in the SCCM Discovery VIRUS COVID-19 registry (NCT04323787), with available discharge data. Dr Anna Cervantes-Arslanian (Boston University School of Medicine, MA, USA) presented the results [1]. Results were also published in Critical Care Explorations in April 2022 [2].
Of the study population, 2,092 (12.9%) developed serious neurological manifestations: 1,656 (10.2%) presented with encephalopathy at admission, 331 (2.0%) had a stroke, 243 (1.5%) had a seizure, and 73 (0.5%) had meningitis/encephalitis at admission or during their stay in the hospital. Risk factors for serious neurological manifestations were older age and higher prevalence of chronic medical conditions, including vascular diseases. Patients with severe neurological manifestation were less likely to have systemic viral symptoms (fever, dyspnoea, and cough) and were less likely to have milder neurological symptoms such as headache, anosmia, and dysgeusia.
All of the serious neurological manifestations were associated with more severe disease, increased ICU support utilisation, and worse outcomes: In patients with serious neurological manifestations the OR for more serious disease, as defined by the WHO ordinal disease severity scale, was 1.82 (P<0.001). The OR for admittance to the ICU was 1.45 (P<0.001). ICU interventions were also more frequent: OR 1.78 for extracorporeal membrane oxygenation (P=0.009) and OR 1.99 for replacement therapy (P<0.001). Hospital and 28-day mortality were higher (OR 1.51 and 1.58; P<0.001), while the number of ICU-free, hospital-free, and ventilator-free days was lower (estimated difference in days -0.84, -1.34, and -0.84; P<0.001).
- Cervantes-Arslanian AM, et al. Neurologic Manifestations of Patients Hospitalized with COVID-19 in the SCCM VIRUS Registry. S18.001, AAN 2022, 02–07 April, Seattle, USA.
- Cervantes-Arslanian AM, et al. Crit Care Explor. 2022;4(4):e0686.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« New evidence for biological basis of “COVID-19 brain fog” Next Article
Interview with Prof. Natalia Rost »
« New evidence for biological basis of “COVID-19 brain fog” Next Article
Interview with Prof. Natalia Rost »
Table of Contents: AAN 2022
Featured articles
Letter from the Editor
Interview with Prof. Natalia Rost
Alzheimer’s Disease and Other Dementias
Targeting senescent cells to treat age-related diseases
Cardiorespiratory fitness protects against dementia
Safety and effects of bosutinib in Lewy body dementia
Epilepsy
“Women with epilepsy should be encouraged to breastfeed”
Fenfluramine: possible new treatment for Lennox-Gastaut syndrome
Laser interstitial thermal therapy for refractory epilepsy
Migraine
Migraine may be an important obstetric risk factor
Intranasal zavegepant safe and well tolerated in healthy adults
Telemedicine during COVID-19 pandemic highly appreciated
Multiple Sclerosis
Ublituximab versus teriflunomide in relapsing MS patients
Ketogenic diet may improve disability and quality of life
Favourable additional safety data for ofatumumab
Predicting new T2 lesions using a machine learning algorithm
Evobrutinib reduces volume of slowly expanding lesions
Sustained long-term efficacy and safety of satralizumab in NMOSD
Muscle and Neuro-Muscular Disorders
Ravulizumab in patients with generalised myasthenia gravis
Gene therapy effective in older patients with spinal muscular atrophy
Losmapimod for facioscapulohumeral muscular dystrophy
SRP-9001 for treating patients with Duchenne muscular dystrophy
Cerebrovascular Disease and Stroke
Intravenous thrombolysis after ischaemic stroke: When in doubt, leave it out?
Better outcomes with mechanical thrombectomy in elderly stroke patients
Plasma NfL levels associated with cardiovascular risk
Non-invasive vagus nerve stimulation for acute stroke
Parkinson’s Disease
Prasinezumab in Parkinson’s disease: delayed-start analysis of PASADENA trial
IPX203 versus immediate release carbidopa-levodopa
Impact of COVID-19 public health interventions
COVID-19
Cognitive, EEG, and MRI features in COVID-19 survivors
Neurological manifestations of COVID-19 worsen prognosis
New evidence for biological basis of “COVID-19 brain fog”
Related Articles
© 2021 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy